Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

story of the week

Published in Metastatic Breast Cancer and

Journal Scan / Research · August 26, 2024

Outcomes of Elacestrant in ER+/HER2− MBC With ESR1-Mutated Tumors Based on Prior Duration of Endocrine Therapy Plus CDK4/6 Inhibitor and Clinical Subgroups

Clinical Cancer Research

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Reshma Mahtani DO

Clinical Cancer Research

Elacestrant in ER+, HER2- MBC with ESR1-mutated tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy Plus CDK4/6 Inhibitor and in Clinical Subgroups

Clin. Cancer Res 2024 Aug 01;[EPub Ahead of Print], A Bardia, J Cortes, FC Bidard, P Neven, J Garcia-Saenz, P Aftimos, J O'Shaughnessy, J Lu, G Tonini, S Scartoni, A Paoli, M Binaschi, T Wasserman, V Kaklamani

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Metastatic Breast Cancer

Outcomes of Elacestrant in ER+/HER2− MBC With ESR1-Mutated Tumors Based on Prior Duration of Endocrine Therapy Plus CDK4/6 Inhibitor and Clinical Subgroups

Additional Info

Elacestrant in ER+, HER2- MBC with ESR1-mutated tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy Plus CDK4/6 Inhibitor and in Clinical Subgroups

Further Reading

Efficacy and Safety of Trastuzumab Deruxtecan Plus Nivolumab in Patients With HER2-Expressing Metastatic Breast or Urothelial Cancer

Predictors of Response to CDK4/6i Retrial After Prior CDK4/6i Treatment Failure in ER+ Metastatic Breast Cancer

Prophylactic Efficacy of Olanzapine-Based Therapy for Trastuzumab Deruxtecan–Associated Nausea and Vomiting in Patients With HER2-Positive or HER2-Low Breast Cancer

Outcomes and Prognostic Factors Associated With Brain Metastasis in Triple-Negative Breast Cancer

Outcomes of Datopotamab Deruxtecan vs Chemotherapy in Previously Treated Patients With Inoperable/Metastatic HR+/HER2− Breast Cancer

Pharmacokinetics and Pharmacogenomics of Ribociclib in Black Patients With Metastatic Breast Cancer

Efficacy and Safety of Elacestrant in ER+/HER2− MBC With ESR1-Mutated Tumors Based on Prior Duration of Endocrine Therapy Plus CDK4/6i and in Clinical Subgroups

Acquired Gene Alterations in Patients Treated With Endocrine Therapy ± Ribociclib Using Baseline and End-of-Treatment ctDNA Samples

Safety of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, HR+/HER2− Advanced or Metastatic Breast Cancer

Outcomes of Pembrolizumab Plus Chemotherapy in Asian Patients With Advanced TNBC

Outcomes of Imlunestrant, an Oral SERD, as Monotherapy and in Combination With Targeted Therapy in ER+/HER2− Advanced Breast Cancer

Recently Updated